The Role of Vitamin D in Prostate Cancer

  • Aruna V. Krishnan
  • Donna M. Peehl
  • David Feldman
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 164)


Prostate cancer (PCa) cells harbor receptors for vitamin D (VDR) as well as androgens (AR). 1,25-dihydroxyvitamin D3[1,(OH)2D3] increases AR expression and enhances androgen actions linking the two receptor systems.1,(OH)2D3exhibits antiproliferative activity in both AR-positive and AR-negative PCa cells. Less calcemic analogs of 1,(OH)2D3, with more antiproliferative activity, are being developed and will be more useful clinically. The mechanisms underlying differential analog activity are being investigated. In target cells, 1,(OH)2D3induces 24-hydroxylase, the enzyme that catalyzes its selfinactivation.Co-treatment with 24-hydroxylase inhibitors enhances the antiproliferative activity of calcitriol. Primary cultures of normal or cancer-derived prostatic epithelial cells express 1a-hydroxylase, the enzyme that catalyzes the synthesis of 1,(OH)2D3, the levels being much lower in the cancerderived cells and in PCa cell lines. This finding raises the possibility of using 25-hydroxyvitamin D3[25(OH)D3] as a chemopreventive agent in PCa.In LNCaP human PCa cells, 1,(OH)2D3and its analogs exert antiproliferative activity predominantly by cell cycle arrest, but also induce apoptosis, although to a much lesser degree. Growth arrest is mediated by induction of IGF binding protein-3 (IGFBP-3), which in turn increases the expression of the cell cycle inhibitor p21, leading to growth arrest. Other actions of 1,(OH)2D3in PCa cells include promotion of pro-differentiation effects and inhibition of tumor cell invasion,metastasis and angiogenesis.


Benign Prostatic Hyperplasia Prostate Cancer Cell LNCaP Cell Human Prostate Cancer Cell Prostatic Epithelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M (2001) 25-hydroxy-vitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 285:1012–1017PubMedCrossRefGoogle Scholar
  2. Blutt SE, Weigel NL (1999) Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221:89–98PubMedCrossRefGoogle Scholar
  3. Blutt SE, Allegretto EA, Pike JW, Weigel NL (1997) 1,25-dihydroxyvitamin D3and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138:1491–1497PubMedCrossRefGoogle Scholar
  4. Blutt SE, McDonnell TJ, Polek TC, Weigel NL (2000) Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10–17PubMedCrossRefGoogle Scholar
  5. Boyle BJ, Zhao XY, Cohen P, Feldman D (2001) Insulin-like growth factor binding protein-3mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319–1324PubMedCrossRefGoogle Scholar
  6. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP (1997) Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15–27PubMedCrossRefGoogle Scholar
  7. Campbell MJ, Park S, Uskokovic MR, Dawson MI, Koeffler HP (1998) Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3analog. Endocrinology 139:1972–1980PubMedCrossRefGoogle Scholar
  8. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera (see comments). Cancer Epidemiol Biomarkers Prev 2:467–472PubMedGoogle Scholar
  9. Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2:389–396PubMedCrossRefGoogle Scholar
  10. Elstner E, Campbell MJ, Munker R, Shintaku P, Binderup L, Heber D, Said J, Koeffler HP (1999) Novel 20-epi-vitamin D3analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 40:141–149PubMedCrossRefGoogle Scholar
  11. Esquenet M, Swinnen JV, Heyns W, Verhoeven G (1996) Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol,all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28:182–194PubMedCrossRefGoogle Scholar
  12. Feldman D (1997) Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J Natl Cancer Inst 89:109–111PubMedCrossRefGoogle Scholar
  13. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer.Nature Rev Cancer 1:34–45CrossRefGoogle Scholar
  14. Feldman D, Glorieux FH, Pike JW (1997) Vitamin D. Academic Press, San Diego Feldman D, Zhao XY, Krishnan AV (2000) Vitamin D and prostate cancer. Endocrinology 141:5–9CrossRefGoogle Scholar
  15. Feldman D, Malloy PJ, Gross C (2001) Vitamin D: biology, action and clinical implications.In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego,pp 257–303Google Scholar
  16. Freedman LP (1999) Transcriptional targets of the vitamin D3receptor-mediating cell cycle arrest and differentiation. J Nutr 129:581S–586SPubMedGoogle Scholar
  17. Gross C, Peehl DM, Feldman D (1997) Vitamin D and prostate cancer. In: Feldman D,Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 1125–1139Google Scholar
  18. Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3(calcitriol). J Urol 159:2035–2040PubMedCrossRefGoogle Scholar
  19. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349PubMedCrossRefGoogle Scholar
  20. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer.CA Cancer J Clin 52:154–179PubMedCrossRefGoogle Scholar
  21. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL (2001) Calcitriol(1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051PubMedGoogle Scholar
  22. Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP (1999) 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast,and myeloid leukemic cells. Cancer Res 59:4023–4029PubMedGoogle Scholar
  23. Hsu JY, Feldman D, McNeal JE, Peehl DM (2001) Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61:2852–2856PubMedGoogle Scholar
  24. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW(1998) Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 58:1620–1623PubMedGoogle Scholar
  25. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P,Galligan MA, Dang HT, Haussler CA, Haussler MR (2000) The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14:401–420Google Scholar
  26. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH (1996) The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7:1563–1570PubMedGoogle Scholar
  27. Konety BR, Johnson CS, Trump DL, Getzenberg RH (1999) Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 17:77–84PubMedGoogle Scholar
  28. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142–153PubMedCrossRefGoogle Scholar
  29. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA (1998) Workgroup I: rodent models of prostate cancer.Prostate 36:49–55PubMedCrossRefGoogle Scholar
  30. Ly LH, Zhao XY, Holloway L, Feldman D (1999) Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071–2076PubMedCrossRefGoogle Scholar
  31. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S (1996) Vitamin D3is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1:97–101PubMedGoogle Scholar
  32. Malloy PJ, Pike JW, Feldman D (1999) The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 20:156–188PubMedCrossRefGoogle Scholar
  33. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B,Kastner P, Mark M, Chambon P et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839PubMedCrossRefGoogle Scholar
  34. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220PubMedCrossRefGoogle Scholar
  35. Miller G (1999) Vitamin D and prostate cancer: biological interactions and clinical potentials.Cancer Met Rev 17:353–360Google Scholar
  36. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA (1995) Vitamin D receptor expression,24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997–1003PubMedGoogle Scholar
  37. Mitra D, Bell NH (1997) Racial, geographic, genetic and body habitus effects on vitamin D metabolism. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 521–532Google Scholar
  38. Moffatt KA, Johannes WU, Miller GJ (1999) 1Alpha,25dihydroxyvitamin D3and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695–703PubMedGoogle Scholar
  39. Morrison N (1997) Vitamin D and prostate cancer. In: Feldman D, Glorieux FH, Pike JW(eds) Vitamin D. Academic Press, San Diego, pp 713–731Google Scholar
  40. Osborn JL, Schwartz GG, Smith DC, Bahnson RR, Day R, Trump DL (1995) Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195–198PubMedCrossRefGoogle Scholar
  41. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D (1994) Antiproliferative effects of 1,25-dihydroxyvitamin D3on primary cultures of human prostatic cells.Cancer Res 54:805–810PubMedGoogle Scholar
  42. Peehl DM, Wong ST, Cramer SD, Gross C, Feldman D (1995) Suramin, hydrocortisone and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D3on prostatic epithelial cells. Urol Oncol 1:188–194PubMedCrossRefGoogle Scholar
  43. Peehl DM, Seto E, Hsu JY, Feldman D (2002) Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analog EB 1089 on prostate cancer cells. J Urol 68:1583–1588Google Scholar
  44. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).Anticancer Res 10:1307–1311PubMedGoogle Scholar
  45. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR (1995) 1,25-Dihydroxy-16-ene-23-yne-vitamin D3and prostate cancer cell proliferation in vivo. Urology 46:365–369PubMedCrossRefGoogle Scholar
  46. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7:391–395PubMedGoogle Scholar
  47. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerstrom G, Westin G(2002) 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967–2972PubMedCrossRefGoogle Scholar
  48. Sharma P, Schreiber-Agus N (1999) Mouse models of prostate cancer. Oncogene 18:5349–5355PubMedCrossRefGoogle Scholar
  49. Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952–1960PubMedCrossRefGoogle Scholar
  50. Skowronski RJ, Peehl DM, Feldman D (1995) Actions of vitamin D3analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 136:20–26PubMedCrossRefGoogle Scholar
  51. Sung V, Feldman D (2000) 1,25-Dihydroxyvitamin D3decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164:133–143PubMedCrossRefGoogle Scholar
  52. Uitterlinden AG, van Leeuwen JPTM, Pols HA (2001) Genetics and genomics of osteoporosis.In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego,pp 639–667Google Scholar
  53. Van Leeuwen JPTM, Pols HAP (1997) Vitamin D: anticancer and differentiation. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 1089–1105Google Scholar
  54. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES,Holick MF, Chen TC (2002) 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81:135–140PubMedCrossRefGoogle Scholar
  55. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E (1989) Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 62:79–87PubMedCrossRefGoogle Scholar
  56. Zhang XH, Jin L, Sakamoto H, Takenaka I (1996) Immunohistochemical localization of metallothionein in human prostate cancer. J Urol 156:1679–1681PubMedCrossRefGoogle Scholar
  57. Zhao XY, Eccleshall TR, Krishnan AV, Gross C, Feldman D (1997a) Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system. Mol Endocrinol 11:366–378CrossRefGoogle Scholar
  58. Zhao XY, Ly LH, Peehl DM, Feldman D (1997b) 1alpha,25-dihydroxyvitamin D3actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290–3298CrossRefGoogle Scholar
  59. Zhao XY, Ly LH, Peehl DM, Feldman D (1999) Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205–1212PubMedCrossRefGoogle Scholar
  60. Zhao XY, Peehl DM, Navone NM, Feldman D (2000) 1alpha,25-dihydroxyvitamin D3inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.Endocrinology 141:2548–2556PubMedCrossRefGoogle Scholar
  61. Zhuang SH, Burnstein KL (1998) Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197–1207PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Aruna V. Krishnan
  • Donna M. Peehl
  • David Feldman
    • 1
  1. 1.Department of Medicine, Division of EndocrinologyStanford University School of MedicineStanfordUSA

Personalised recommendations